A recent study using MDA-MB-231 breast cancer cell models found that the treatment with four commercially available CO-RMs, including CORM-1, CORM-2, CORM-3, and CORM-A1, significantly reduced the levels of excreted VEGF in these breast cancer cells, among which CORM-2 showed the highest efficacy followed by CORM-3 [87]. The gene discussed is VEGFA; the disease is breast carcinoma.